A Novel EPO Receptor Agonist Improves Glucose Tolerance via Glucose Uptake in Skeletal Muscle in a Mouse Model of Diabetes
Table 1
Hyperinsulenemic euglycemic clamp characteristics in DIO mice treated with single IV administration of CNTO 530 (0.03 mg/kg and 0.3 mg/kg). Insulin clamp was performed at one and fourteen days after drug administration. The results are presented as mean ± SEM. #indicates a P value < .05 relative to control group.
Day 1
Day 14
PBS
0.03 mg/kg
0.3 mg/kg
PBS
0.03 mg/kg
0.3 mg/kg
Body weight, g
45.7 ± 1.5
46.6 ± 1.7
44.7 ± 1.8
46.9 ± 1.5
43 ± 4.8
42.9 ± 4.8
Hemoglobin, mmol/L
8.6 ± 0.3
8.4 ± 0.5
8.4 ± 0.3
9.3 ± 0.3
10.0 ± 0.2#
11.3 ± 0.2#
Fasting glucose, mmol/L
5.5 ± 0.3
5.4 ± 0.4
5.5 ± 0.6
4.7 ± 0.4
4.5 ± 0.3
2.8 ± 0.15#
Fasting plasma insulin, ng/mL
1.9 ± 0.3
2.4 ± 0.5
2.1 ± 0.4
1.8 ± 0.2
2.1 ± 0.4
1.8 ± 0.3
Fasting HGP, μmoL/min.kg
29.5 ± 0.6
39.1 ± 6.3
36.3 ± 2.3#
41.6 ± 3.6
47.1 ± 4.4
38.5 ± 2.8
Fasting glucose oxidation, dpm/μL
65 ± 9
52 ± 12
55 ± 9
85 ± 7
86 ± 4
70 ± 5
GIR, μmoL/min.kg
26.3 ± 2.6
26.6 ± 4.1
36.9 ± 4.2
26.7 ± 4.5
33.9 ± 3.9
60.2 ± 5.2#
Plasma insulin during hyperinsulinemic clamp, ng/mL
